May 29, 2020
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer at ASCO 2020
Mar 06, 2019
Real World Evidence on Use of Halaven® (eribulin mesylate) Injection Following CDK 4/6 Inhibitor to be Presented at 36th Annual Miami Breast Cancer Conference
Mar 04, 2019
Cyclododecanone (CAS 830-13-7): 2019 Market Research Report - ResearchAndMarkets.com
Nov 27, 2018
Eisai to Present New Research on HALAVEN® (eribulin mesylate) Injection at 41st Annual San Antonio Breast Cancer Symposium
Apr 09, 2018
Morphotek Announces Agreement to License its Proprietary Eribulin-Linker Payload to Bliss Biopharmaceutical Co., Ltd. for Development of a Therapeutic Antibody-Drug Conjugate (ADC)*
Jan 10, 2018
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Dec 08, 2017
Encouraging Updated Results from Phase 1b/2 Study Evaluating the Combination of Eribulin Mesylate and Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer Presented at the 2017 SABCS
Dec 07, 2017
Morphotek To Present Its Proprietary RESPECT(TM) Antibody-Drug Conjugate (ADC) Technology At The Upcoming Antibody Engineering & Therapeutics Conference In San Diego
Dec 04, 2017
Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression
Nov 13, 2017
Morphotek To Present Its Proprietary RESPECT(TM) Antibody Drug Conjugate (ADC) Technology At The Upcoming 9th Annual PEGS Europe In Lisbon
Sep 11, 2017
Medivir Announces Janssen to Discontinue Development of JNJ-4178 for Hepatitis C
Jul 25, 2017
Medivir AB - Interim Report, January - June 2017